Skip to main content

Gibson Christopher's Form 4 filing

Recursion Pharmaceuticals, Inc. (RXRX) · filed Apr 8, 2022

Accession no.
0001209191-22-023903
Filed
Apr 8, 2022
Trade date
Apr 6, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 10 non-derivative transactions and 5 derivative transactions. Open-market sales total $259.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gibson ChristopherCIK 0001856369Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 6, 2022Class A Common StockMOption exerciseAcquired+44,010$2.48+$109,144.8306,068Direct
Apr 6, 2022Class A Common StockSSaleDisposed−17,326$7.00F2−$121,282288,742Direct
Apr 6, 2022Class A Common StockCConversionAcquired+18,500$0.00F4$0307,242Direct
Apr 6, 2022Class A Common StockSSaleDisposed−18,500$6.56F5−$121,360288,742Direct
Apr 6, 2022Class A Common StockCConversionAcquired+500$0.00F4$0500Indirect
Apr 6, 2022Class A Common StockSSaleDisposed−500$6.55F6−$3,2750Indirect
Apr 6, 2022Class A Common StockCConversionAcquired+1,000$0.00F4$01,000Indirect
Apr 6, 2022Class A Common StockSSaleDisposed−1,000$6.57F7−$6,5700Indirect
Apr 6, 2022Class A Common StockCConversionAcquired+1,000$0.00F4$01,000Indirect
Apr 6, 2022Class A Common StockSSaleDisposed−1,000$6.56F7−$6,5600Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 6, 2022Class A Common StockCConversionDisposed−6,985,334$0.00F4$06,985,334Direct
Apr 6, 2022Class A Common StockMOption exerciseDisposed−1,383,334$0.00$01,383,334Direct
Apr 6, 2022Class A Common StockCConversionDisposed−549,000$0.00F4$0549,000Indirect
Apr 6, 2022Class A Common StockCConversionDisposed−548,000$0.00F4$0548,000Indirect
Apr 6, 2022Class A Common StockCConversionDisposed−144,875$0.00F4$0144,875Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $6.983 to $7.003. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F4

Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

Referenced by the price of 4 transactions in Table I and 4 transactions in Table II.

F5

This transaction was executed in multiple trades at prices ranging from $6.36 to $7.025. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $6.37 to $7.025. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $6.37 to $7.028. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)